Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response

IF 23.7 Q1 MICROBIOLOGY
iMeta Pub Date : 2024-11-20 DOI:10.1002/imt2.248
Yuzhao Jin, Songhua Cai, Yang Zhou, Dandan Guo, Yuzhen Zeng, Wangting Xu, Yiting Sun, Yueli Shi, Zhiyong Xu, Zaoqu Liu, Peng Luo, Zhao Huang, Bufu Tang
{"title":"Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response","authors":"Yuzhao Jin,&nbsp;Songhua Cai,&nbsp;Yang Zhou,&nbsp;Dandan Guo,&nbsp;Yuzhen Zeng,&nbsp;Wangting Xu,&nbsp;Yiting Sun,&nbsp;Yueli Shi,&nbsp;Zhiyong Xu,&nbsp;Zaoqu Liu,&nbsp;Peng Luo,&nbsp;Zhao Huang,&nbsp;Bufu Tang","doi":"10.1002/imt2.248","DOIUrl":null,"url":null,"abstract":"<p>After RFA treatment in patients with liver cancer, the expression of <i>SLC7A11</i>/xCT and the proportion of DCs in the TME were significantly increased. <i>SLC7A11</i>/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":"3 6","pages":""},"PeriodicalIF":23.7000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.

Abstract Image

以SLC7A11/xCT为靶点,通过树突状细胞介导的抗肿瘤免疫应答提高肝癌射频消融疗效。
肝癌患者经RFA治疗后,TME中SLC7A11/xCT的表达及DCs的比例均显著升高。SLC7A11/xCT是肝癌预后不良的标志物,主要在TME的dc中表达。在dc中靶向xCT联合RFA可显著增强抗肿瘤免疫,抑制肿瘤生长,为改善肝癌治疗结果提供了有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信